Dr Lal PathLabs Share Price in Focus; To Acquire 70% Stake in SN Genelab for Up to ₹168 Crore

Written by: Team Angel OneUpdated on: 28 Sept 2026, 9:39 pm IST

Dr Lal PathLabs to acquire 70% of SN Genelab for up to ₹168 crore, with completion expected by November 30, 2026, under the cash deal.

Dr Lal PathLabs has approved the purchase of a 70% stake in SN Genelab Private Limited (SN Gene) from its existing shareholders, as per an exchange filing dated September 24, 2026.

SN Gene will become a subsidiary of Dr Lal PathLabs after the transaction.

Total Deal Value

The acquisition will be made through cash consideration. Dr Lal PathLabs will pay up to ₹168 crore for the 70% stake, according to the company’s disclosure. The deal also includes a performance-linked earn-out capped at ₹31.5 crore.

The transaction does not fall under related party transactions, the company said. No government or regulatory approval has been specified as being required for completing the acquisition.

SN Gene’s Financials

SN Gene operates in diagnostics, with a focus on genomics services. The company reported turnover of ₹57.96 crore in FY2026, compared with ₹53.36 crore in FY2025 and ₹43.27 crore in FY2024.

The company was incorporated on December 16, 2013, in Gujarat. Its business is centred on providing diagnostics-genomics services.

Also Check: Healthcare Stocks

Dr Lal PathLabs Genomics Business

Dr Lal PathLabs has stated that the acquisition is intended to add to its expertise in genomics and expand its portfolio of advanced diagnostic services. The transaction will give it a controlling interest in SN Gene, while the disclosure does not specify any purchase of the remaining 30% stake.

Completion Timeline

The transaction is expected to be completed by November 30, 2026. The acquisition involves SN Gene’s existing shareholders and will be funded through cash rather than a share swap.

The deal puts a value of up to ₹168 crore on the 70% stake, excluding the separate performance-linked earn-out of up to ₹31.5 crore. SN Gene reported ₹57.96 crore in turnover in FY2026.

As of September 25, 2026, 11:30 am, Dr Lal PathLabs share price was trading at ₹1,929.10, a 1.64% decrease from the previous closing price.

Conclusion

The acquisition will give Dr Lal PathLabs a 70% stake in SN Genelab, which operates in diagnostics-genomics.The deal includes a performance-linked earn-out capped at ₹31.5 crore.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Looking to invest? Open a Demat Account with Angel One and start trading seamlessly.

Published on: Sep 25, 2026, 12:11 PM IST

Team Angel One

Team Angel One is a group of experienced financial writers that deliver insightful articles on the stock market, IPO, economy, personal finance, commodities and related categories.

Know More